Danaher Corporation (DHR)

Core revenue grew ~4% in 2025 after declining in 2024. Bioprocessing is recovering off a low base but still below 2022 peak levels. Diagnostics is growing low-single digits. TMO and ABT are recovering faster in similar end markets. Danaher's growth is adequate but not leading its peer group.

Cytiva maintains #2 position in bioprocessing behind Sartorius, with strong share in single-use technologies. Beckman Coulter is holding share in clinical diagnostics. Pall Life Sciences is well-positioned in filtration. No major share losses, but no significant gains either — the market is mature and competitive.

Danaher benefits from installed-base consumable pricing (reagents, filters, bags) but the bioprocessing destocking revealed that customers can delay purchases longer than expected. Pricing is positive but modest (~2-3% annually). Not in the same league as ISRG or SHW for pricing power.

New product introductions in genomics (Beckman) and connected workflow solutions are incremental rather than transformative. The DBS system drives continuous improvement but doesn't generate breakthrough innovation. Danaher is an operator, not an innovator — and that's fine, but it limits upside momentum.

Biopharma customers validate their manufacturing processes with specific Cytiva/Pall consumables — changing suppliers requires costly and time-consuming revalidation with regulators. Clinical labs running Beckman Coulter analyzers are locked into proprietary reagent systems. These switching costs are structural and durable.

Limited network effects in life sciences tools. Some benefit from workflow integration across Danaher platforms (e.g., Beckman + Leica in pathology labs), but these are cross-sell synergies, not true network effects. The installed base creates pull for consumables but doesn't strengthen with each additional user.

Bioprocessing consumables used in FDA-approved manufacturing processes become part of the regulatory filing — competitors can't easily displace them. Diagnostic instruments require FDA/CE clearance. Danaher's patent portfolio in filtration, chromatography, and diagnostics is deep. Regulatory moats are the strongest part of the investment case.

Danaher's asset-light consumables model generates 25%+ free cash flow margins. The DBS system enables Danaher to acquire businesses and improve their margins by 500-1000bps within 3-5 years. This operational leverage is a genuine competitive advantage that's difficult to replicate.

EPS estimates for 2026 have been roughly flat over the past 6 months — modest upward revisions offset by slower-than-expected bioprocessing recovery. The street is modeling ~10% EPS growth, which requires bioprocessing orders to accelerate through 2026. Revisions aren't negative, but they're not generating enthusiasm.

The narrative has shifted from 'destocking disaster' to 'recovery underway' — a clear improvement. GLP-1 drug manufacturing is a new growth driver narrative for bioprocessing. However, China biopharma weakness and slower-than-expected mRNA manufacturing demand are headwinds to the bull case. The stock is in no-man's-land between deep value and growth re-acceleration.

Rainer Blair has been a solid but unspectacular CEO. The Veralto spinoff was value-creating. M&A has been quiet — Danaher has $15B+ in acquisition firepower but hasn't deployed it, frustrating investors who expect the serial-acquirer playbook. Capital allocation is disciplined (buybacks, dividends) but lacks the catalytic M&A that historically drove re-ratings.